A Phase Ib, Dose-Escalation Study of Augmented Lymphodepletion and CAR T-cell Priming With Low-dose Total Body Irradiation in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphomas and Multiple Myeloma Receiving Treatment With Commercial CD19 or BCMA-directed CAR T-cell Therapies

This is a clinical trial to evaluate the safety of combining CAR T-cell therapy with low-dose total body irradiation (LD-TBI) in patients with previously treated large B-cell lymphoma (LBCL) or multiple myeloma (MM). The investigators' hypothesis is that the combination will make the immune system more active in fighting cancer by increasing the display of antigens and activating pathways that lead to cell death, including death receptors like FAS and TRAIL2. This approach is expected to help the CAR T cells grow and last longer, leading to stronger anti-tumor effects and more cancer cell deaths. Participants will receive LDTBI treatment before their CAR T cell therapy and will be followed up for 2 years.

开始日期2026-08-01

申办/合作机构

Weill Medical College of Cornell University

NCT07093554

/ Recruiting临床1期IIT

Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Myeloma

This is a single-arm, open-label, phase 1b study evaluating the safety and feasibility of using talquetamab as bridging therapy prior to cilta-cel in patients with relapsed and refractory multiple myeloma (RRMM).

开始日期2025-12-02

申办/合作机构

Medical College of Wisconsin

NCT07149857

/ Recruiting临床2期

A Phase 2 Multicohort Trial to Further Characterize the Efficacy and Safety of Ciltacabtagene Autoleucel

The purpose of this study is to evaluate how well (efficacy) cilta-cel works when given with a fludarabine-free lymphodepletion regimen (a process of reducing the number of lymphocytes, a type of white blood cell in the body, typically through chemotherapy), or an alternative administration of cilta-cel infusion following a cyclophosphamide and fludarabine lymphodepletion regimen.

开始日期2025-10-03

申办/合作机构

Janssen Research & Development LLC

100 项与西达基奥仑赛相关的临床结果

登录后查看更多信息

100 项与西达基奥仑赛相关的转化医学

登录后查看更多信息

100 项与西达基奥仑赛相关的专利（医药）

登录后查看更多信息

452

项与西达基奥仑赛相关的文献（医药）

2026-12-31·Human Vaccines & Immunotherapeutics

Knowledge mapping and research trends of chimeric antigen receptor T-cell immunotherapy in breast cancer: A bibliometric and visual analytics study

Article

作者: Yi, Qiyi ; Xu, Yu ; Bian, Po ; Xu, Yuechen ; Wang, Fan ; Wang, Zhisen

Chimeric antigen receptor T cell (CAR-T) immunotherapy has achieved landmark success in hematologic malignancies and is being explored for breast cancer (BC) and other solid tumors, prompting research to improve efficacy and safety. We retrieved 894 related to CAR-T immunotherapy for BC from the Web of Science Core Collection and performed bibliometric analyses using CiteSpace and VOSviewer to map the research landscape, development trajectory, and key contributors. Joinpoint regression assessed temporal trends in annual publications using R 4.4.2. The USA led publication output. Institutional co-occurrence revealed the University of London and Technische Universität Dresden as central hubs. CANCER RES and FRONT IMMUNOL were identified as core journals. Darcy PK and Morgan RA were prominent authors by output and citations. Keyword clustering and timeline visualization indicated that the terms "in vivo," "tumor microenvironment (TME)," and "targeted therapy" have remained highly active in recent years. In addition, burst detection analysis revealed that keywords including TME, "epithelial-mesenchymal transition," and "mesothelin" have gradually emerged as research frontiers, suggesting increasing attention to resistance mechanisms and tumor immune regulation. These findings provide a systematic overview of the evolving research landscape and help identify emerging hotspots and future directions. BC remains the most frequently diagnosed malignancy among women worldwide and a major cause of cancer-related death. We systematically mapped the knowledge structure and development trends of CAR-T research in BC, identifying major research contributors and emerging research hotspots, which may provide valuable insights for future basic research and clinical exploration in this field.

2026-12-31·JOURNAL OF MEDICAL ECONOMICS

Real-world healthcare resource utilization and clinical outcomes among patients with relapsed/refractory multiple myeloma receiving ciltacabtagene autoleucel after four or more prior lines of therapy in inpatient versus outpatient settings

Article

作者: Maitland, Jessica ; Perciavalle, Matthew ; Janakiram, Murali ; Nagar, Saurabh P. ; Ghosh, Sabyasachi ; Bixby, Todd ; Fan, Lin ; Dima, Danai ; Qureshi, Zaina P. ; Emond, Bruno ; Alegria, Victoria

BACKGROUND:

Ciltacabtagene autoleucel (cilta-cel) has demonstrated remarkable efficacy in relapsed or refractory multiple myeloma (RRMM). Outpatient (OP) administration of cilta-cel is increasingly used to improve access and reduce healthcare resource utilization (HCRU) compared to inpatient (IP) administration. We compared all-cause HCRU and clinical outcomes of IP versus OP administration of cilta-cel in patients with RRMM after ≥4 prior lines of therapy (LOT) in clinical practice.

METHODS:

We identified adults receiving cilta-cel between 02/28/2022 and 06/30/2024 after ≥4 prior LOT using Komodo Research Database claims data and classified patients into cohorts by setting of administration (IP/OP). All-cause HCRU, treatment-free interval (TFI), overall survival (OS), and clinical events (e.g. cytokine release syndrome [CRS], immune effector cell-associated neurotoxicity syndrome [ICANS]) were assessed. Outcomes were compared using multivariate regression and reported as incidence rate ratios (IRR) with 95% confidence intervals (CI).

RESULTS:

Among 242 patients, 148 (61.2%) received cilta-cel in IP and 94 (38.8%) in OP. Baseline characteristics were comparable between cohorts. Of patients in the OP cohort, 31.9% did not require an IP admission within 3 months post-infusion. During this period, the OP cohort had significantly fewer IP days per-patient-per-month (2.4 vs. 6.6; IRR [95% CI]: 0.37 [0.28; 0.48], p < 0.001) and more OP days (8.5 vs 5.4; IRR [95% CI]: 1.43 [1.26; 1.63], p < 0.001) than the IP cohort. From the fourth month post-infusion, no significant differences in HCRU were observed. Rates of CRS and ICANS, and long-term outcomes including 6 and 12 month TFI and OS were similar.

CONCLUSION:

OP administration of cilta-cel yielded similar effectiveness and safety outcomes relative to IP administration, while significantly reducing IP resource use. These findings support the feasibility of OP administration of cilta-cel in treating RRMM patients and its potential to reduce the burden on the healthcare system.

2026-10-01·PHARMACOLOGY & THERAPEUTICS

Harnessing multispecific antibodies for next-generation cancer treatments

Review

作者: Fan, Xing-Xing ; Zheng, Xiao-Li ; Liu, Wen-Qian

Multispecific antibodies (MsAbs), capable of targeting multiple antigens simultaneously, are regarded as the 2.0 version of monoclonal antibodies (mAbs), providing therapeutic benefits that significantly exceed those of mAbs. This enhanced functionality makes MsAbs a particularly promising strategy for treating solid tumors. In this comprehensive review, we summarize diverse targeting strategies, clinical trial outcomes, and existing hurdles, while proposing novel directions to enhance the development of MsAbs for overcoming the immunosuppressive tumor microenvironment (TME). Based on their therapeutic mechanisms, we categorize their actions into six principles: 1) blocking various oncogenic signaling pathways; 2) activating and redirecting cytotoxic immune cells toward tumor cells; 3) enhancing macrophage-mediated phagocytosis; 4) targeting immune checkpoints to alleviate immunosuppression; 5) modulating matrix components within the immunosuppressive TME; and 6) promoting immune cell infiltration and localized cytokine signaling. In addition, the integration of MsAbs with sophisticated technologies has opened new avenues for enhancing therapeutic efficacy. These approaches include antibody-degrader conjugates, chimeric antigen receptor T cell (CAR-T) therapies, antibody-oncolytic virus combinations, nanomaterial-based delivery systems, and messenger RNA (mRNA)-based technologies. Such innovative strategies highlight the transformative potential of MsAbs, positioning them at the forefront of next-generation cancer immunotherapies.

3,281

项与西达基奥仑赛相关的新闻（医药）

2026-08-28

·今日头条

细胞科技一周资讯：全球首款外泌体疗法11月迎FDA终审

▍江苏正式出台《江苏省促进生物医药产业高质量发展三年行动计划》为加快培育具有国际竞争力的生物医药产业集群，打造生物医药新兴支柱产业，江苏省工业和信息化厅8月26日正式对外发布《江苏省促进生物医药产业高质量发展三年行动计划》，目标到2028年，全省生物医药产业规模、创新药械数量保持全国领先，打造一批具有核心竞争力的生物医药产业集聚区。 ▍ 上肢衰退减缓54%！全球首款外泌体疗法11月迎FDA终审当地时间8月24日，Capricor Therapeutics宣布，FDA已将其在研细胞疗法Deramiocel（CAP-1002）治疗杜氏肌营养不良症（DMD）的BLA的PDUFA目标行动日期，从2026年8月22日延期至11月22日。该BLA于2024年12月以心肌病方向提交，依据II期HOPE-2研究及其开放标签延伸研究的心脏数据；2025年7月曾收到FDA完全回应函，本次为第二次审查。 ▍ 2026 年上半年 CAR-T 销售额出炉：超 30 亿美元 2025 年，全球 7 款获 FDA 批准上市 CAR‑T 药物全年总销售额为 59.67 亿美元，同比增长 31.66%。其中，强生/传奇生物 Carvykti、吉利德 Yescarta 以及 BMS Breyanzi 三款头部药物合计贡献 47.4 亿美元，占总规模的 79%。进入 2026 年上半年，5 款具备完整统计口径的 CAR-T 药物合计实现销售额超 30 亿美元，赛道马太效应持续强化。 ▍ NMPA 发布《国家重点研发计划重点专项管理实施细则》近日，国家药监局发布了《国家药品监督管理局主责国家重点研发计划重点专项管理实施细则》的征求意见稿，文件强调了国家药监局作为「主责单位」的角色，即：国家药监局从以往的参与者转变为医药领域重点专项的牵头组织者和责任者。

2026-08-28

·今日头条

一针318万！AI造的抗癌疫苗火了，普通人却只能看着

2026年8月19日，生物医药圈炸了。美国药企莫德纳（Moderna）和默沙东（Merck）联合官宣：双方耗时近十年研发的个性化mRNA黑色素瘤疫苗Intismeran Autogene（研发代号mRNA-4157/V940），在Ⅲ期临床试验INTerpath-001中取得关键性成功。这项试验纳入了1137名已手术切除的高危黑色素瘤患者（ⅡB期至Ⅳ期），结果显示：疫苗联合PD-1抑制剂K药（帕博利珠单抗）使用，在无复发生存期（RFS）和无远处转移生存期（DMFS）两大核心终点上，均显著优于单独使用K药。这是全球首个闯过Ⅲ期临床验证的mRNA个性化癌症治疗性疫苗。消息一出，资本市场直接疯了。莫德纳股价单日暴涨177%，收于174.38美元，市值一夜飙升445亿美元。全网刷屏，"人类距离攻克癌症又近了一步""医学奇迹"之类的评论铺天盖地。可狂欢的余温还没散，一盆冷水就浇了下来。美国投资银行William Blair随后发布定价测算：这款疫苗的批发采购价格（WAC）预计高达每名患者47.5万美元，折合人民币约318万元。 318万。这个数字什么概念？在国内多数二线城市能买一套刚需房，是普通工薪家庭十几年甚至几十年的总收入。评论区的画风瞬间变了——从"医学万岁"变成了"这跟我有什么关系""富人的续命工具""穷人的命不是命"。一边是人类对抗癌症的重大突破，一边是绝大多数家庭无力承担的天价门槛。这款被寄予厚望的抗癌疫苗，转眼就被贴上了"富人专属游戏"的标签。我花了几天时间，翻完了能找到的所有公开资料——临床试验设计、药企财报、分析师报告、行业专家访谈，想搞清楚几个问题：这款疫苗到底值不值这个价？318万的天价是怎么算出来的？国内患者有没有可能用上？医学进步，难道注定只能先服务富人？答案比我预想的复杂。它到底是什么：AI量身定制，一人一苗先说清楚，这款疫苗不是普通人理解的"防癌疫苗"。它不是打了以后不得癌症的预防性疫苗，而是治疗性疫苗——给已经确诊、已经做了手术的黑色素瘤患者用的，目的是激活人体自身免疫系统，清除体内残存的微小癌细胞，降低术后复发和远处转移的概率。而且它必须和K药联合使用，单独打疫苗没用。最核心的特点是完全个性化定制。每一支疫苗都是独一无二的，世界上不存在两支一模一样的Intismeran。整个流程是这样的：第一步，医生从患者手术切除的肿瘤组织里取样，同时抽一管外周血作为正常对照。第二步，对肿瘤样本进行全外显子测序和RNA测序，找出癌细胞独有的基因突变——这些突变产生的异常蛋白，叫"新抗原"，是免疫系统识别癌细胞的"靶子"。第三步，关键来了。一个癌细胞可能有几十上百个突变，但不是每个突变都能触发有效的免疫反应。这时候人工智能算法上场了——它会根据突变的免疫原性、HLA结合能力、表达量等多个维度，从海量突变里快速筛选出最多34个最有可能触发免疫反应的新抗原靶点。第四步，根据筛选出的靶点，设计专属的mRNA序列，在GMP车间里合成、制剂、质控，最终做成一支只属于这位患者的疫苗。第五步，冷链运输到医院，给患者注射。整个疗程一共打9针，持续约一年。从取样到拿到疫苗，整套流程需要6到9周。 AI在这个过程中起到的作用是决定性的。以前靠人工生物信息学团队筛选新抗原靶点，耗时数月，准确率还不到六成。现在AI算法几周就能完成海量数据比对，精准识别高免疫原性的靶点，不仅大幅缩短了制备周期，还提升了免疫应答的效率。这也是为什么这款疫苗被称为"AI研制的抗癌疫苗"——不是说AI凭空造了一种药，而是AI在靶点筛选这个核心环节上，把不可能变成了可能。临床数据确实亮眼。在更早的Ⅱ期临床试验KEYNOTE-942中，157名患者接受了疫苗联合K药治疗，5年随访数据显示：复发或死亡风险降低49%（HR=0.510），远处转移或死亡风险降低59%。对于高危黑色素瘤患者来说，这意味着接近一半的复发风险被压了下去。要知道，黑色素瘤被称为"皮肤癌之王"，恶性程度极高，极易复发和远处转移。高危Ⅲ、Ⅳ期患者术后单独用K药，复发率依然居高不下。一旦复发转移，后续治疗费用飙升，联合免疫治疗年费用可超过25万美元，患者还要承受巨大的痛苦。所以从医学价值上说，这款疫苗的突破是实打实的。它证明了一条全新的抗癌路线——基于mRNA的个性化新抗原免疫治疗——是走得通的。未来这条技术路线可以拓展到肺癌、肾癌、胰腺癌、结直肠癌等数十种癌症，一旦成熟，将彻底改写全球肿瘤治疗的格局。这也是资本市场为之疯狂的原因。Jefferies分析师预测，Intismeran全球峰值销售额可能达到540亿美元。但问题是，医学价值归医学价值，价格归价格。 47.5万美元是怎么算出来的 47.5万美元，约318万人民币，这个数字不是药企自己报的，是投行William Blair的预测。 William Blair明确说了，这个定价参照的是已经获批的肿瘤细胞治疗——也就是CAR-T疗法。目前美国已上市的CAR-T产品，定价普遍在37万到47万美元之间。比如诺华的Kymriah定价47.5万美元，吉利德的Yescarta定价37.3万美元，强生的Carvykti定价46.5万美元。 William Blair认为，Intismeran作为同样高度个性化、同样定制化生产的肿瘤疗法，定价对标CAR-T是合理的，所以给出了47.5万美元的预测。但这个预测在分析师圈子里是偏高的。其他机构的预测要低不少：Jefferies估的是26万美元，另有分析师估单疗程约20万美元。也就是说，最终定价可能在20万到47.5万美元之间，William Blair的47.5万是最悲观（对患者来说）的预测。不管最终定在哪个档位，有一点是确定的：这款药便宜不了。为什么？因为它的成本结构，从根上就决定了它不可能像普通药片那样几块钱一片。第一，研发投入巨大。医药行业有个"双十定律"——一款创新药从立项到上市，平均需要10年时间、投入超10亿美元。莫德纳这些年持续押注mRNA技术，2025年公司全年营收仅19亿美元，亏损28亿美元，研发费用就花了31亿美元。为了维持管线，公司还签了15亿美元的五年期贷款。这些前期沉没成本，最终都要通过商业化定价收回来。第二，患者群体太小，摊薄不了成本。黑色素瘤虽然凶险，但全球发病率极低。国际癌症研究机构数据显示，全球黑色素瘤标化发病率仅3.2/10万。中国更低，只有0.37/10万，每年新发患者约8800例。这么小的患者基数，没法像新冠疫苗、降压药那样靠巨大销量摊薄成本，单位患者分摊的研发成本自然居高不下。第三，也是最核心的——一人一苗的定制化生产模式。传统药物可以在流水线上大规模生产，一批药做出来供几万甚至几十万人用，边际成本持续递减。但Intismeran不一样，每一支都要单独测序、单独设计、单独合成、单独质控，相当于每个患者都要"开一条独立生产线"。行业咨询机构Alacrita的白皮书测算，目前个性化mRNA癌症疫苗的单患者生产成本就超过10万美元。这还只是生产端的直接成本，没算研发分摊、冷链物流、医院诊疗、K药联合用药的费用。 K药本身也不便宜。在美国，K药的年治疗费用标价在12万到17万美元之间。也就是说，就算疫苗只卖20万美元，加上K药，患者一年的总治疗费用也要30多万美元，折合人民币200多万。所以47.5万美元的预测，看似离谱，但放在个性化肿瘤疗法的定价体系里，并非空穴来风。国内患者：看着很近，其实很远对中国患者来说，这款疫苗的距离，比318万的价格还要远。首先是上市时间。莫德纳CEO Stéphane Bancel在8月24日对外表示，希望2027年Intismeran能在美国获批。也就是说，最快2027年底、2028年初才能在美国上市。中国呢？目前Intismeran并未在国内开展临床试验。业内专家推算，中国正式上市至少还要4到5年，也就是2030年以后才有可能。其次是适应症差异。这款疫苗目前只针对皮肤型黑色素瘤，也就是欧美患者最常见的类型——由紫外线照射引发的皮肤黑色素瘤。但中国患者的黑色素瘤，70%以上是肢端型和黏膜型——长在手掌、脚掌、指甲下、鼻腔、口腔、消化道等部位，和紫外线没关系，基因突变特征和欧美人群差异显著。这意味着，即便这款药进入中国，也需要重新开展本土化临床试验，验证它对中国患者常见的肢端型、黏膜型黑色素瘤是否有效。在数据出来之前，国内医生不会贸然给患者用。第三是支付问题。目前国内医保目录内的抗肿瘤药物，大多经过大幅降价谈判，年治疗费用普遍控制在10万元以内。300多万的天价药物，短期内不可能进入医保。商业保险也很难覆盖这类小众高端疗法——国内绝大多数百万医疗险，对海外上市、国内未获批的药物是免责的。对国内普通患者而言，这款疫苗更像是一条遥远的医学新闻，而非触手可及的治疗方案。网上有不少声音指责药企"收割财富""把救命药卖成奢侈品"。但医药行业的从业者有另一套逻辑。一位在创新药公司做了十几年的朋友跟我说："你觉得贵，是因为你只看到了这一支药的价格。你没看到的是，在这款药成功之前，莫德纳烧了几十亿美元做了无数个失败的项目。如果成功的药不能卖出高价收回成本，就没有公司愿意再投钱做下一款药了。到最后，受损失的还是患者。" 这话有道理，但也只说了一半。创新药需要高回报来激励研发，这是商业逻辑。但当价格高到脱离大众承受范围，医学进步的普惠性就会大打折扣。最终形成的局面是——富人能用上最先进的疗法续命，普通人只能用传统方案听天由命。这不是某一家药企的问题，而是整个全球医疗体系都在面临的结构性矛盾。 CAR-T疗法已经给我们展示了这个矛盾。2017年第一款CAR-T上市，定价47.5万美元，当时也是一片"富人专属"的质疑。九年过去了，CAR-T的价格依然居高不下，全球能用上的患者寥寥无几。中国虽然有了国产CAR-T，定价降到了120万人民币，但对绝大多数家庭来说，依然是天文数字。 Intismeran会不会重蹈CAR-T的覆辙？目前看，可能性很大。未来会便宜吗？会，但需要时间尽管当下的价格让人绝望，但业内普遍认为，这只是mRNA抗癌技术发展的早期阶段，未来成本下降是必然趋势。下降的动力来自几个方面。一是技术迭代。目前AI筛选靶点的算法还在快速进化，测序成本也在持续下降。十年前全基因组测序要几万美元，现在只要几百美元。未来随着AI算法优化、自动化定制生产线落地，疫苗制备周期会从6到9周缩短到更短，生产成本有望在5到10年内下降50%以上。二是适应症扩大。目前只做黑色素瘤，患者基数小。未来如果拓展到肺癌、乳腺癌、结直肠癌等高发癌症，患者群体扩大几十倍，单位成本自然会被摊薄。Jefferies的预测里，Intismeran未来在非小细胞肺癌、肾细胞癌等适应症上的峰值份额，甚至会超过黑色素瘤。三是国产替代。中国也在加快本土mRNA抗癌技术的布局。国内多家生物医药企业已经启动个性化新抗原疫苗的临床研究，依托国内庞大的患者样本、低成本基因测序优势，未来国产同类疗法上市后，定价大概率会远低于海外药企。就像国产PD-1把进口K药、O药的价格从几十万打到几万一样，国产mRNA癌症疫苗也可能把价格打下来。但这些都需要时间。至少未来3到5年内，Intismeran的价格不会出现断崖式下降。对现在正在和黑色素瘤搏斗的患者来说，他们等不起。还有一个值得关注的趋势：药企正在探索"按疗效付费"的模式。也就是如果患者打了疫苗后还是复发了，药企退款或打折。这种模式在CAR-T领域已经有过尝试，如果能推广到mRNA癌症疫苗，至少能降低患者"花了钱却没用"的风险。翻完所有资料，我最大的感受不是"这款疫苗好厉害"，也不是"太贵了用不起"，而是一种复杂的无力感。医学进步的速度，和普通人能享受到医学进步的速度，中间隔着一道巨大的鸿沟。一款新药从实验室走到患者床边，要十年、几十亿美元；从获批上市到进入医保、让普通人用得起，又要好几年。在这期间，能第一时间用上的，永远是少数人。这不是某一家公司的错，也不是某一个国家的问题，而是整个人类医疗体系的现实。但我依然觉得，这款疫苗的成功是好事。哪怕它现在卖47.5万美元一针，哪怕国内患者还要等好几年，哪怕大多数人用不起——它至少证明了，个性化mRNA抗癌这条路是走得通的。有路，就有希望。十年前，PD-1抑制剂刚上市的时候，年费用也超过10万美元，被认为是富人药。十年后，国产PD-1已经进了医保，年费用降到几万块，普通患者也能用了。 mRNA癌症疫苗可能也会走同样的路。今天47.5万美元的天价，或许十年后会变成十几万、几万块。技术成熟了，产能上去了，国产替代来了，价格自然会下来。这需要时间，需要耐心，也需要更多的投入和竞争。莫德纳CEO Bancel说，他们的目标是让癌症成为一种可以管理的慢性病，而不是死刑判决。这个目标很宏大，但如果每一款新药都定价47.5万美元，那这个目标最终只会属于付得起钱的人。医学发展的初心，从来都不是为少数人续命，而是让更多人拥有对抗病魔的底气。希望有一天，最顶尖的抗癌技术，不再是富人专属的奢侈品，而是所有患者都能触手可及的希望。那一天可能还很远，但至少，我们已经在路上了。

2026-08-27

·北京医学感染与传染研究

自然医学 32卷 7-8期

Nature Medicine Volume 32 Issue 7 自然医学 32卷 7期 https://www.nature.com/nm/volumes/32/issues/7 Editorial（社论） 1 Oncology must confront hidden side effects 肿瘤学必须正视隐匿不良反应 Nature Medicine volume 32（7）, page 2321 News（新闻） 2 Taming the inflamed heart 调控炎症性心脏病变 Charlotte Harrison Nature Medicine volume 32（7）, pages 2322-2323 News Feature（新闻专题） 3 When the real world becomes the trial 当现实世界成为临床试验场域 Marianne Guenot Nature Medicine volume 32（7）, pages 2324–2327 Correspondence（读者来信） 4 What Galen’s dissections reveal about tacit learning in modern medical education 盖伦解剖研究对现代医学教育中默会学习的启示 Andres PelavskiGabriele TorcolettiOrly Lewis Nature Medicine volume 32（7）, pages 2328–2329 5 What Utah’s clinical AI sandbox reveals about independent oversight 犹他州临床人工智能沙箱对独立监管机制的启示 Rahul GorijavoluNikhil JaiswalLeo Anthony Celi Nature Medicine volume 32（7）, pages 2330–2332 6 A case of artificial intelligence-enhanced diagnostics leading to heart transplantation 人工智能辅助诊断促成心脏移植一例 Heidi S. HartmanJoshua FinerPierre Elias Nature Medicine volume 32（7）, pages 2333–2334 7 Unintended consequences of legacy oversight in digital medicine 数字医学领域传统监管模式带来的非预期后果 Jochen K. LennerzDaniela AllendeAnne M. Stowman Nature Medicine volume 32（7）, pages 2335–2337 8 Incretin therapies, nutrition and food insecurity in the UK 英国肠促胰素治疗、营养状况与粮食不安全问题 Marie SpreckleyCara F. RuggieroAdrian Brown Nature Medicine volume 32（7）, pages 2338–2339 World View（全球观点） 9 Manageable toxicity is not a label — it is an oxymoron 可控制毒性并非标签，而是矛盾表述 From the patient’s perspective, toxicity is manageable only when it is met with empathy. 从患者视角而言，只有饱含人文关怀，不良反应才谈得上可控。 Laura Book Nature Medicine volume 32（7）, page 2340 10 Downplaying toxicities in cancer drug trials is not acceptable 肿瘤药物临床试验中淡化不良反应不可取 Bishal Gyawali Nature Medicine volume 32（7）, page 2341 Comment（述评） 11 Wearables as personal health custodians 可穿戴设备：个人健康守护者 Lei LuJosip Car Nature Medicine volume 32（7）, pages 2342–2345 12 Australia legislates against genetic discrimination in life insurance 澳大利亚立法禁止人寿保险领域的基因歧视 Jane Tiller Nature Medicine volume 32（7）, pages 2346–2348 13 A roadmap to competitive preclinical packages 具备竞争力的临床前研究方案构建路线图 Mustafa KhasrawMegan C. BenzJose R. Conejo-Garcia Nature Medicine volume 32（7）, pages 2349–2352 14 Brain Health for Economic Resilience: a data-driven framework for the brain-positive economic transition 保障大脑健康助力经济韧性：推动益脑经济转型的数据驱动框架 Harris A. EyreRym AyadiSimon Fischer-Baum Nature Medicine volume 32（7）, pages 2353–2355 News & Views（新闻与观点） 15 Long-term health risks of e-cigarettes after smoking cessation 戒烟后使用电子烟的长期健康风险 Mahdi SheikhPamela M. Ling Nature Medicine volume 32（7）, pages 2356–2357 16 CAR T cells take on precancers CAR-T细胞靶向癌前病变 Eric M. JurgensSham Mailankody Nature Medicine volume 32（7）, pages 2358–2359 17 Lassa fever countermeasures gather pace 拉沙热防控举措加速推进 Daniel Jenkin Nature Medicine volume 32（7）, pages 2360–2361 18 Shifting the goalposts in obesity drug development 肥胖药物研发目标的重新界定 W. Timothy Garvey Nature Medicine volume 32（7）, pages pages 2362–2363 Research Briefings（研究简报） 19 General-purpose chatbots outperform clinical AI tools on physicians’ real-world questions 通用对话机器人在医师现实临床问题上表现优于专用临床人工智能工具 Nature Medicine volume 32（7）, pages 2364–2365 20 An AI framework for multi-disease detection via retinal imaging 基于视网膜影像的多疾病筛查人工智能框架 Nature Medicine volume 32（7）, pages 2366–2367 Perspectives（前瞻观点） 21 Immune aging biomarkers for clinical trials 适用于临床试验的免疫衰老生物标志物 Andrea CiprianoJamie JusticeChiara M. S. Herzog Nature Medicine volume 32（7）, pages 2368–2382 Review Articles（综述） 22 Biological aging clocks in health and disease 健康与疾病状态下的生物学衰老时钟 Tony Wyss-CorayEric J. Topol Nature Medicine volume 32（7）, pages 2383–2394 Matters Arising（学术争鸣） 23 Limited evidence of AI superiority in seasonal influenza vaccine strain selection 尚无充分证据证明人工智能在季节性流感疫苗毒株筛选中具备优势 Simon P. J. de JongColin A. Russell Nature Medicine volume 32（7）, pages 2395–2397 24 Reply to: Limited evidence of AI superiority in seasonal influenza vaccine strain selection 对《尚无充分证据证明人工智能在季节性流感疫苗毒株筛选中具备优势》一文的回应 Wenxian ShiJeremy WohlwendRegina Barzilay Nature Medicine volume 32（7）, pages 2398–2400 Brief Communications（简讯） 25 Spatiotemporal diffusion of the 2024 Oropouche outbreak in Cuba 2024年古巴奥罗普切热暴发的时空传播特征 Rosario GravierMelissa M. PerezMaria G. Guzman Nature Medicine volume 32（7）, pages 2401–2404 26 General-purpose large language models outperform specialized clinical AI tools on medical benchmarks 通用大语言模型在医学基准测试中优于专用临床人工智能工具 Krithik VishwanathAnton AlyakinEric Karl Oermann Nature Medicine volume 32（7）, pages 2405–2409 Articles（论著） 27 Electronic cigarette use after smoking cessation and lung cancer risk 戒烟后使用电子烟与肺癌风险 Yeon Wook KimEung Joo ParkChoon-Taek Lee Nature Medicine volume 32（7）, pages 2410–2419 28 Ciltacabtagene autoleucel in high-risk smoldering multiple myeloma: the CAR-PRISM phase 2 trial Ciltacabtagene autoleucel治疗高危冒烟型（无症状）多发性骨髓瘤：CAR-PRISMⅡ期临床试验 Omar NadeemDavid M. Cordas dos SantosIrene M. Ghobrial Nature Medicine volume 32（7）, pages 2420–2429 29 Cibisatamab and FAP-4-1BBL in microsatellite-stable colorectal cancer: a phase 1b trial Cibisatamab联合FAP-4-1BBL治疗微卫星稳定型结直肠癌：Ⅰb期临床试验 Ignacio MeleroTamara TanosVictor Moreno Nature Medicine volume 32（7）, pages 2430–2439 30 Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: a phase 2 trial 基于Teclistamab的诱导方案治疗适合移植初诊多发性骨髓瘤：Ⅱ期临床试验 Marc S. RaabNiels WeinholdK. Martin Kortüm Nature Medicine volume 32（7）, pages 2440–2448 31 Anti-LAG-3 with or without anti-PD-1 in recurrent glioblastoma: a phase 1 trial 抗LAG-3单抗联合或不联合抗PD-1单抗治疗复发性胶质母细胞瘤：Ⅰ期临床试验 Michael LimXiaobu YeStuart A. Grossman Nature Medicine volume 32（7）, pages 2449–2460 32 Neoadjuvant stereotactic body radiation therapy with durvalumab and oleclumab in ER+HER2− breast cancer: a randomized phase 2 trial 立体定向体部放疗联合度伐利尤单抗与奥来鲁单抗新辅助治疗ER阳性HER2阴性乳腺癌：随机Ⅱ期临床试验 Alex De CaluwéIsabelle DesmoulinsLaurence Buisseret Nature Medicine volume 32（7）, pages 2461–2472 33 Post-adjuvant chemotherapy in ctDNA-positive patients with resected colorectal cancer: a randomized phase 3 trial ctDNA阳性结直肠癌术后辅助化疗：随机Ⅲ期临床试验 Hideaki BandoJun WatanabeTakeshi Kato Nature Medicine volume 32（7）, pages 2473–2480 34 Multi-antigen-targeting T cells in pediatric central nervous system tumors: a phase 1 trial 多抗原靶向T细胞治疗儿童中枢神经系统肿瘤：Ⅰ期临床试验 Stephanie GomezRachel A. DiCioccioEugene I. Hwang Nature Medicine volume 32（7）, pages 2481–2493 35 AI framework for multidisease detection via retinal imaging 基于视网膜影像的多疾病筛查人工智能框架 Xiayin ZhangQinyi LiHonghua Yu Nature Medicine volume 32（7）, pages 2494–2503 36 Long-term independent use of an intracortical brain–computer interface for speech and cursor control 皮层内脑机接口用于语音与光标控制的长期独立应用研究 Nicholas S. CardTyler Singer-ClarkDavid M. Brandman Nature Medicine volume 32（7）, pages 2504–2510 37 Adjuvanted inactivated rabies virus-vectored Lassa virus vaccine in healthy adults: a phase 1 trial 含佐剂灭活狂犬病毒载体拉沙病毒疫苗在健康成人中的Ⅰ期临床试验 Justin R. OrtizDrishya KurupMatthias J. Schnell Nature Medicine volume 32（7）, pages 2511–2521 38 Favipiravir for Lassa fever: an open-label, randomized controlled phase 2 trial 法匹拉韦治疗拉沙热：开放标签随机对照Ⅱ期临床试验 Cyril EramehKevin OkwaraekeMirjam Groger Nature Medicine volume 32（7）, pages 2522–2532 39 Bispecific 10E8.4/iMab broadly neutralizing antibody in people with or without HIV-1: a partially randomized phase 1 trial 双特异性广谱中和抗体10E8.4/iMab在HIV-1感染者与健康人群中的部分随机Ⅰ期临床试验 Deborah A. TheodoreBryan T. MayerMagdalena E. Sobieszczyk Nature Medicine volume 32（7）, pages 2533–2545 40 15-strain live biotherapeutic product or same donor fecal microbiota transplant for recurrent Clostridioides difficile infection: a randomized phase 1b trial 15菌株活体生物制剂与同源供体粪菌移植治疗复发性艰难梭菌感染：随机Ⅰb期临床试验 Lukas BethlehemLorenza BartuAri Grinspan Nature Medicine volume 32（7）, pages 2546–2555 41 Innate immune responsiveness predicts enhanced cellular immunity and symptomatic disease after controlled human influenza infection 固有免疫应答水平可预测人工流感感染后细胞免疫增强与临床发病情况 Loukas PapargyrisJiayun XuChristopher Chiu Nature Medicine volume 32（7）, pages 2556–2569 42 Efficacy and target engagement of dopamine agonist pramipexole for anhedonic depression: a randomized placebo-controlled trial 多巴胺激动剂普拉克索治疗快感缺失型抑郁症的疗效与靶点作用验证：随机安慰剂对照试验 Filip VentorpMarie AspDaniel Lindqvist Nature Medicine volume 32（7）, pages 2570–2578 43 Spinal cord stimulation for upper limb motor function in people with chronic post-stroke hemiparesis: a feasibility trial 脊髓电刺激改善慢性卒中后偏瘫患者上肢运动功能：可行性临床试验 Roberto M. de FreitasShovan BhatiaMarco Capogrosso Nature Medicine volume 32（7）, pages 2579–2590 44 A neuroprosthesis for restoring hand movement and sensation in a person with complete tetraplegia 神经假体用于重建完全四肢瘫痪患者手部运动与感觉功能 Santosh ChandrasekaranSarah K. WandeltChad E. Bouton Nature Medicine volume 32（7）, pages pages2591–2601 45 Dual-target gene therapy in Parkinson’s disease: a multicenter phase 1 trial 双靶点基因疗法治疗帕金森病：多中心Ⅰ期临床试验 Mengyue NiuJifeng GuoJun Liu Nature Medicine volume 32（7）, pages 2602–2609 46 Abatacept versus hydroxychloroquine for prevention of rheumatoid arthritis in individuals with palindromic rheumatism: a randomized open-label trial 阿巴西普对比羟氯喹预防复发性风湿症进展为类风湿关节炎：随机开放标签试验 Raimon SanmartiCarolina Pérez-GarcíaIsabel Haro Nature Medicine volume 32（7）, pages 2610–2618 47 Oligonucleotide–siRNA conjugate for SOD1 amyotrophic lateral sclerosis: a phase 1 trial 寡核苷酸-siRNA偶联药物治疗SOD1相关肌萎缩侧索硬化：Ⅰ期临床试验 Weiqi ChenLingling JiangYilong Wang Nature Medicine volume 32（7）, pages 2619–2628 48 Multinational validation of the PREVENT and SCORE2心血管风险方程 across 6.4 million individuals 基于640万人群的多国验证：PREVENT与SCORE2心血管风险预测方程 Brendon L. NeuenRupert W. MajorVilmantas Giedraitis Nature Medicine volume 32（7）, pages 2629–2638 49 Cliramitug for depletion of cardiac amyloid transthyretin: long-term follow-up of the NI006-101 trial Cliramitug清除心脏转甲状腺素蛋白淀粉样物质：NI006-101试验长期随访结果 Peter C. KahrFabian aus dem SiepenPeter van der Meer Nature Medicine volume 32（7）, pages 2639–2646 50 Low-dose digoxin in patients with heart failure with reduced or mildly reduced ejection fraction: a randomized controlled trial 小剂量地高辛治疗射血分数降低或轻度降低心力衰竭：随机对照试验 D. J. van VeldhuisenM. RienstraP. van der Meer Nature Medicine volume 32（7）, pages 2647–2653 51 The microRNA inhibitor CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: a randomized phase 2 trial 微小RNA抑制剂CDR132L治疗心肌梗死后左室射血分数降低患者：随机Ⅱ期临床试验 Johann BauersachsScott D. SolomonThomas Thum Nature Medicine volume 32（7）, pages 2654–2661 52 Semaglutide versus placebo in individuals with poor weight loss after bariatric surgery: a double-blinded, randomized, placebo-controlled trial 司美格鲁肽对比安慰剂治疗减重手术术后减重不佳人群：双盲随机安慰剂对照试验 Chloe StanleyRitwika MallikJanine Makaronidis Nature Medicine volume 32（7）, pages 2662–2672 53 Apitegromab for lean mass preservation during tirzepatide-induced weight loss: a randomized, double-blind, placebo-controlled phase 2 trial Apitegromab用于替尔泊肽减重过程中维持瘦体重：随机双盲安慰剂对照Ⅱ期临床试验 Richard E. PratleyDouglas Scott DenhamJing L. Marantz Nature Medicine volume 32（7）, pages 2673–2678 54 Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial Orforglipron用于维持减重效果：双盲随机Ⅲb期ATTAIN-MAINTAIN试验 Louis J. AronneDeborah B. HornNeena Xavier Nature Medicine volume 32（7）, pages 2679–2687 Amendments & Corrections（勘误与更正） 55 Author Correction: Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: a phase 2 trial 作者更正：基于Teclistamab的诱导方案治疗适合移植初诊多发性骨髓瘤：Ⅱ期临床试验 Marc S. RaabNiels WeinholdK. Martin Kortüm Nature Medicine volume 32（7）, page 2688 56 Author Correction: Digital AVATAR therapy for distressing voices in psychosis: the phase 2/3 AVATAR2 trial 作者更正：数字虚拟化身疗法治疗精神病幻听症状：Ⅱ/Ⅲ期AVATAR2临床试验 Philippa A. GaretyClementine J. EdwardsThomas Ward Nature Medicine volume 32（7）, page 2689 57 Author Correction: Global burden of amphetamine, cannabis, cocaine and opioid use in 204 countries, 1990–2023: a Global Burden of Disease Study 作者更正：1990–2023年204个国家苯丙胺、大麻、可卡因与阿片类物质使用的全球疾病负担研究 Jiseung KangHyeon Jin KimDong Keon Yon Nature Medicine volume 32（7）, page 2690 58 Retraction Note: Time-of-day immunochemotherapy in non-small cell lung cancer: a randomized phase 3 trial 撤稿声明：时辰免疫化疗治疗非小细胞肺癌：随机Ⅲ期临床试验 Zhe HuangLiang ZengYongchang Zhang Nature Medicine volume 32（7）, page 2691 Nature Medicine Volume 32 Issue 8 自然医学 32卷 8期 https://www.nature.com/nm/volumes/32/issues/8 Editorial（社论） 1 Anti‑aging interventions need less hype and more clinical evidence 抗衰老干预：少一些炒作，多一些临床证据 Editorial Nature Medicine volume 32（8）, page 2693 News（新闻） 2 A turning point for gene editing in severe blood disorders 基因编辑治疗重症血液疾病迎来转折点 Carrie Arnold Nature Medicine volume 32（8）, pages 2694-2696 News Feature（新闻特写） 3 Sleep as therapy 睡眠疗法 Carrie Arnold Nature Medicine volume 32（8）, pages 2697–2700 Correspondence（通信） 4 Genetic–exposome interactions and aging clocks in dementia: the ReDLat2 initiative 遗传‑暴露组相互作用与痴呆衰老时钟：ReDLat2研究计划 Agustin IbáñezJennifer S. YokoyamaBruce L. Miller Nature Medicine volume 32（8）, pages 2701–2703 5 Bundibugyo Ebola without vaccines or therapeutics: why public health fundamentals matter more than border closures 无疫苗与治疗药物情况下的本迪布焦埃博拉疫情：公共卫生基础措施比边境封锁更为重要 Ngashi NgongoMosoka Papa FallahJean Kaseya Nature Medicine volume 32（8）, pages 2704–2705 6 Fertilizer scarcity as a failure of global health governance 肥料短缺：全球卫生治理的一项失败 Alaha NasariAmina NasariJessica Fanzo Nature Medicine volume 32（8）, pages 2706–2707 7 Mapping the human chemical exposome for public health 面向公共卫生的人类化学暴露组图谱绘制 Arthur DavidSarah LennonMichel Samson Nature Medicine volume 32（8）, pages 2708–2710 World View（全球视野） 8 When caution becomes harm 当谨慎变为伤害 Simone N. Vigod Nature Medicine volume 32（8）, page 2711 Comment（述评） 9 Enabling secure discovery in trusted research environments with improved tooling 依托优化工具在可信研究环境中实现安全数据挖掘 Vincent J. StraubMelinda C. Mills Nature Medicine volume 32（8）, pages 2712–2715 10 Reinventing biotech systems for patient impact 重塑生物技术体系，惠及患者 Kushal T. KadakiaYashodhara DashAnaeze C. Offodile II Nature Medicine volume 32（8）, pages 2716–2719 11 Why large‑scale randomized trials of live‑attenuated shingles vaccination for dementia prevention are urgently needed 亟需开展减毒活带状疱疹疫苗预防痴呆的大规模随机对照试验 Pascal Geldsetzer Nature Medicine volume 32（8）, pages 2720–2723 12 Inspiring, shaping and sustaining an African research & development agenda 推动、构建并维系非洲研发议程 Mosoka P. FallahMisaki WayengeraJean Kaseya Nature Medicine volume 32（8）, pages 2724–2726 13 Data rights are the missing pillar for modernizing consent in medicine 数据权利：医学知情同意现代化的缺失支柱 Nada S. Salem Nature Medicine volume 32（8）, pages 2727–2728 Q&A（问答） 14 Reinventing health communication for the digital era 数字时代下重塑健康传播 Natalie Healey Collection: Nature Medicine Commission on Quality Health Information for All Nature Medicine volume 32（8）, pages 2729–2731 News & Views（新闻与观点） 15 Adaptive brain stimulation 2.0 for Parkinsonian gait 用于帕金森病步态障碍的第二代自适应脑刺激 Arjun BalachandarAlfonso Fasano Nature Medicine volume 32（8）, pages 2732–2734 16 A second chance for gene therapy to restore natural hearing 基因治疗重获契机，助力恢复天然听力 Nicola Strenzke Nature Medicine volume 32（8）, pages 2735–2737 17 From RAS inhibitor resistance to rational combination strategies 从RAS抑制剂耐药到合理联合治疗策略 Paula LynchTeresa MacarullaGrainne M. O’Kane Collection: Cancer at Nature Portfolio Nature Medicine volume 32（8）, pages 2738–2740 18 Deciphering the role of histidine in cancer 解析组氨酸在肿瘤中的作用 Feyza CansizAmanda N. PopeAlpaslan Tasdogan Nature Medicine volume 32（8）, pages 2741–2742 Research Briefings（研究简报） 19 Learning from routine health system data builds better neuroimaging AI models 基于常规卫生系统数据训练构建更优神经影像人工智能模型 Research Briefing Nature Medicine volume 32（8）, pages 2743–2744 20 Early detection of Alzheimer’s disease with circular RNA from blood 基于血液环状RNA实现阿尔茨海默病早期检测 Nature Medicine volume 32（8）, pages 2745–2746 21 Non‑invasive tests for the evaluation of liver fibrosis in MASLD 代谢相关脂肪性肝病肝纤维化的无创评估检测 Nature Medicine volume 32（8）, pages 2747–2748 22 Multi‑omics maps human–pig interactions in extracorporeal liver cross‑circulation 多组学解析体外肝交叉循环中人‑猪相互作用 Nature Medicine volume 32（8）, pages 2749–2750 23 Biological aging might help to explain the rising risk of early‑onset cancer 生物衰老或可解释早发性肿瘤风险升高现象 Nature Medicine volume 32（8）, pages 2751–2752 24 Delivering the benefits of genomic data reanalysis for diagnosis equitably and at scale 公平、规模化发挥基因组数据再分析的诊断价值 Nature Medicine volume 32（8）, pages 2753–2754 25 Why high scores do not mean application readiness for health AI 为何高分不等于健康人工智能具备实际应用就绪度 Nature Medicine volume 32（8）, pages 2755–2756 Perspectives（观点） 26 Type 2 diabetes prevention across the life course 全生命周期的2型糖尿病预防 Yiying WangJennifer L. SargentAndreas L. Birkenfeld Nature Medicine volume 32（8）, pages 2757–2773 27 The next generation of antibody–drug conjugates 新一代抗体‑药物偶联物 F. MoseleA. PeltierF. André Collection: Cancer at Nature Portfolio Nature Medicine volume 32（8）, pages 2774–2785 Brief Communications（简讯） 28 Clinical profile and genomic characterization of the 2026 Bundibugyo virus index case in Uganda 乌干达2026年本迪布焦病毒首发病例的临床特征与基因组分析 Andrew NsawotebbaIsaac SsewanyanaDiana Atwine Nature Medicine volume 32（8）, pages 2786–2789 Articles（论著） 29 Immersive virtual reality with synchronous neurostimulation for upper‑limb recovery after stroke: a randomized feasibility trial 沉浸式虚拟现实联合同步神经刺激用于脑卒中后上肢功能恢复：一项随机可行性试验 Giuseppe Valerio AurucciOlivera DjordjevicStanisa Raspopovic Nature Medicine volume 32（8）, pages 2790–2802 30 Adaptive deep brain stimulation for dynamic gait control in Parkinson’s disease: a randomized feasibility trial 自适应深部脑刺激用于帕金森病动态步态调控：一项随机可行性试验 Kenneth H. LouieJannine P. BalakidDoris D. Wang Nature Medicine volume 32（8）, pages 2803–2814 31 Activity‑dependent adaptive deep brain stimulation improves gait in Parkinson’s disease 活动依赖性自适应深部脑刺激改善帕金森病患者步态 Stefano ScafaValeria de SetaEduardo M. Moraud Nature Medicine volume 32（8）, pages 2815–2830 32 Health system learning enables generalist neuroimaging models 基于卫生系统数据学习构建通用型神经影像模型 Akhil KondepudiAkshay RaoTodd Hollon Nature Medicine volume 32（8）, pages 2831–2837 33 Individualized antisense oligonucleotides for SCN2A‑related developmental epileptic encephalopathy 针对SCN2A相关发育性癫痫性脑病的个体化反义寡核苷酸治疗 Olivia Kim‑McManusLaurence MignonElizabeth Berry‑Kravis Nature Medicine volume 32（8）, pages 2838–2845 34 Re‑administration of AAV‑mediated gene therapy for OTOF‑related deafness: a single‑arm trial OTOF相关耳聋腺相关病毒介导基因治疗的再次给药：一项单臂临床试验 Xintai FanLonglong ZhangYilai Shu Nature Medicine volume 32（8）, pages 2846–2856 35 Blood‑based circular RNAs for early diagnosis of Alzheimer’s disease 基于血液环状RNA的阿尔茨海默病早期诊断 Bridget PhillipsJessie SanfordCarlos Cruchaga Nature Medicine volume 32（8）, pages 2857–2864 36 Acquired resistance to the RAS(ON) multi‑selective inhibitor daraxonrasib guides rational combination therapy strategies in pancreatic cancer RAS(ON)高选择性抑制剂daraxonrasib获得性耐药指导胰腺癌合理联合治疗策略 Ida AronchikSumit KarMallika Singh Collection: Cancer at Nature Portfolio Nature Medicine volume 32（8）, pages 2865–2877 37 MAGE‑A4/MAGE‑A8‑targeted TCR‑based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial 靶向MAGE‑A4/MAGE‑A8的TCR双特异性T细胞衔接分子治疗复发/难治性实体瘤：Ⅰ期临床试验 Martin WermkeSebastian OchsenreitherCarsten Reinhardt Nature Medicine volume 32（8）, pages 2878–2887 38 Savolitinib in MET‑amplified gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial 赛沃替尼治疗MET扩增胃癌或胃食管结合部腺癌：Ⅱ期临床试验 Zhi PengTianshu LiuZhongxian Zheng Nature Medicine volume 32（8）, pages 2888–2897 39 SEZ6‑targeting antibody−drug conjugate ABBV‑706 in advanced small cell lung cancer and solid tumors: a phase 1 trial 靶向SEZ6抗体‑药物偶联物ABBV‑706治疗晚期小细胞肺癌及其他实体瘤：Ⅰ期临床试验 Lauren Averett ByersByoung Chul ChoSreenivasa Chandana Nature Medicine volume 32（8）, pages 2898–2908 40 FcRH5×CD3 bispecific antibody cevostamab in relapsed or refractory multiple myeloma: a phase 1 trial FcRH5×CD3双特异性抗体ce vostamab治疗复发难治多发性骨髓瘤：Ⅰ期临床试验 Adam D. CohenJoshua RichterAmrita Krishnan Nature Medicine volume 32（8）, pages 2909–2917 41 Metabolic determinants of cancer immunotherapy outcomes identified by plasma profiling 基于血浆谱分析筛选肿瘤免疫治疗疗效的代谢决定因素 Déborah SuissaMarine FidelleLaurence Zitvogel Nature Medicine volume 32（8）, pages 2918–2932 42 Polypill for heart failure with reduced ejection fraction: the POLY‑HF randomized trial 射血分数降低心力衰竭复方制剂：POLY‑HF随机临床试验 Ambarish PandeyNeil KeshvaniThomas J. Wang Nature Medicine volume 32（8）, pages 2933–2940 43 Oral small molecule GLP‑1 receptor agonist aleniglipron in people with overweight or obesity: a randomized, double‑blind, placebo‑controlled phase 2b trial 口服小分子GLP‑1受体激动剂aleniglipron治疗超重/肥胖人群：随机双盲安慰剂对照Ⅱb期临床试验 Julio RosenstockIldiko LingvayBlai Coll Nature Medicine volume 32（8）, pages 2941–2947 44 Survodutide in adults with obesity and metabolic dysfunction‑associated steatotic liver disease: SYNCHRONIZE‑MASLD, a randomized, double‑blind, placebo‑controlled phase 3 trial Survodutide治疗合并代谢相关脂肪性肝病的肥胖成人：SYNCHRONIZE‑MASLD随机双盲安慰剂对照Ⅲ期临床试验 Lee M. KaplanElena StartsevaPaul Hellstern Nature Medicine volume 32（8）, pages 2948–2958 45 Prospective validation of imaging and serum diagnostic biomarkers of steatohepatitis and fibrosis in MASLD: the LITMUS Imaging Study 代谢相关脂肪性肝炎及肝纤维化影像与血清诊断生物标志物的前瞻性验证：LITMUS影像研究 Michael PavlidesYasaman ValiQuentin M. Anstee Nature Medicine volume 32（8）, pages 2959–2969 46 Longitudinal multiomics profiling of extracorporeal cross‑circulation with pig liver xenografts in human decedents 人逝者猪肝异种移植体外交叉循环的纵向多组学分析 Qian GuoChan WangBrendan J. Keating Nature Medicine volume 32（8）, pages 2970–2982 47 Biological aging and generational shifts in early‑onset cancer risk 生物衰老与早发性肿瘤风险的代际变迁 Ruiyi TianXiaoyu ZongYin Cao Nature Medicine volume 32（8）, pages 2983–2990 48 Automated reanalysis of genomic data for rare disease diagnostics at scale 面向大规模罕见病诊断的基因组数据自动化再分析 Matthew J. WellandK. D. AhlquistZornitza Stark Nature Medicine volume 32（8）, pages 2991–2999 49 Divergent impacts of explainable AI for dermatological diagnosis on clinicians versus lay people 可解释人工智能皮肤病诊断对临床医师与普通人群的差异化影响 Xuhai ‘Orson’ XuHaoyu HuMarzyeh Ghassemi Nature Medicine volume 32（8）, pages 3000–3009 50 Generalizable AI predicts immunotherapy outcomes across cancers and treatments 泛化人工智能跨肿瘤类型与治疗方案预测免疫治疗疗效 Wanxiang ShenIntae MoonMarinka Zitnik Nature Medicine volume 32（8）, pages 3010–3022 51 Evaluating the robustness and readiness of large frontier models in health AI applications 健康人工智能应用中大前沿模型的稳健性与就绪度评估 Yu GuJingjing FuPaul Vozila Nature Medicine volume 32（8）, pages 3023–3031 52 Generative AI‑enabled clinical decision support system in primary care: a pragmatic, cluster‑randomized trial 基层医疗机构生成式人工智能临床决策支持系统：一项实用整群随机试验 Ambrose AgweyuPaul MwanikiBilal A. Mateen Nature Medicine volume 32（8）, pages 3032–3039 53 Integrated care pathway in individuals with Long COVID: STIMULATE‑ICP, a cluster‑randomized, phase 3 trial 长新冠患者综合护理路径：STIMULATE‑ICP整群随机Ⅲ期临床试验 Amitava BanerjeeGordon PrescottYi Mu Nature Medicine volume 32（8）, pages 3040–3047 54 Maternal 6‑valent group B Streptococcus vaccine in non‑pregnant and pregnant females: a randomized phase 1/2 trial B族链球菌六价母体疫苗在非妊娠及妊娠女性中的随机Ⅰ/Ⅱ期临床试验 Shabir A. MadhiHasra SnaggsAlejandra Gurtman Nature Medicine volume 32（8）, pages 3048–3059 55 The genetic architecture of fibromyalgia across 2.5 million individuals 基于250万人群的纤维肌痛遗传结构研究 Isabel KerrebijnGyda BjornsdottirMichael Wainberg Nature Medicine volume 32（8）, pages 3060–3070 56 Povorcitinib for hidradenitis suppurativa: the randomized, double‑blind, placebo‑controlled STOP‑HS1 and STOP‑HS2 phase 3 trials Povorcitinib治疗化脓性汗腺炎：随机双盲安慰剂对照STOP‑HS1、STOP‑HS2两项Ⅲ期临床试验 Martina L. PorterAntonio MartorellChristos C. Zouboulis Nature Medicine volume 32（8）, pages 3071–3081 Analysis（分析） 57 A meta‑analysis of the long‑term effects of antihypertensive therapy on the risk of major cardiovascular disease across 51 randomized trials 纳入51项随机试验的降压治疗对主要心血管病风险长期影响的荟萃分析 Qianqian YangZeinab BidelKazem Rahimi Nature Medicine volume 32（8）, pages 3082–3092 Amendments & Corrections（修订与勘误） 58 Author Correction: SEZ6‑targeting antibody−drug conjugate ABBV‑706 in advanced small cell lung cancer and solid tumors: a phase 1 trial 作者勘误：靶向SEZ6抗体‑药物偶联物ABBV‑706治疗晚期小细胞肺癌及其他实体瘤：Ⅰ期临床试验 Lauren Averett ByersByoung Chul ChoSreenivasa Chandana Nature Medicine volume 32（8）, page 3093 59 Author Correction: MAGE‑A4/MAGE‑A8‑targeted TCR‑based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial 作者勘误：靶向MAGE‑A4/MAGE‑A8的TCR双特异性T细胞衔接分子治疗复发/难治性实体瘤：Ⅰ期临床试验 Martin WermkeSebastian OchsenreitherCarsten Reinhardt Nature Medicine volume 32（8）, page 3094 60 Publisher Correction: Oral small molecule GLP‑1 receptor agonist aleniglipron in people with overweight or obesity: a randomized, double‑blind, placebo‑controlled phase 2b trial 出版方勘误：口服小分子GLP‑1受体激动剂aleniglipron治疗超重/肥胖人群：随机双盲安慰剂对照Ⅱb期临床试验 Julio RosenstockIldiko LingvayBlai Coll Nature Medicine volume 32（8）, page 3095

100 项与西达基奥仑赛相关的药物交易

登录后查看更多信息

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
难治性多发性骨髓瘤	日本	Janssen Pharmaceutical KK	2022-08-03
复发性多发性骨髓瘤	日本	Janssen Pharmaceutical KK	2022-08-03
多发性骨髓瘤	美国	南京传奇生物科技有限公司	2022-02-28
多发性骨髓瘤	美国	Janssen Biotech, Inc.	2022-02-28

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
阴燃多发性骨髓瘤	临床2期	美国	Janssen Research & Development LLC	2023-04-19
复发性浆细胞骨髓瘤	临床2期	-	南京传奇生物科技有限公司	2015-10-02
多发性骨髓瘤的髓外病变	临床1期	澳大利亚	Janssen LP	2023-12-08

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ASCO2026	N/A	多发性骨髓瘤	60	Prophylactic cyclophosphamide (PPX CTX)	獵遞鬱選簾艱壓獵壓簾(壓膚窪窪夢襯糧遞鹽夢) = PPX CTX was well tolerated, with 2 cases of grade 1 nausea reported. 願襯顧醖鑰築願壓鑰壓 (鹽鏇築醖夢網艱簾窪鑰 )	不佳	2026-05-29
				Prophylactic dexamethasone (PPX DEX)
NCT04181827 (CARTITUDE-4, ASCO2026)	临床2期	难治性多发性骨髓瘤	104	Ciltacabtagene autoleucel (High-risk cytogenetics)	餘餘製餘範壓網製積願(築簾衊構艱糧膚築淵膚) = 遞廠醖糧遞製夢壓醖遞範醖醖醖築糧鑰襯夢顧 (淵憲淵網窪襯鏇鬱夢鑰 ) 更多	积极	2026-05-29
				Ciltacabtagene autoleucel (Standard-risk cytogenetics)	餘餘製餘範壓網製積願(築簾衊構艱糧膚築淵膚) = 襯鏇願觸顧醖網繭齋醖範醖醖醖築糧鑰襯夢顧 (淵憲淵網窪襯鏇鬱夢鑰 ) 更多
NCT04181827 (CARTITUDE-4, EHA2026)	临床2期	难治性多发性骨髓瘤	104	CILTACABTAGENE AUTOLEUCEL (high-risk cytogenetics)	鏇齋選蓋艱鏇網鹹選憲(鹹鹹衊獵積獵廠廠蓋醖) = 蓋鬱廠廠齋鏇築觸壓齋壓簾壓壓醖願範範艱鏇 (顧蓋壓蓋遞顧顧繭窪壓 ) 更多	积极	2026-05-21
				CILTACABTAGENE AUTOLEUCEL (standard-risk cytogenetics)	鏇齋選蓋艱鏇網鹹選憲(鹹鹹衊獵積獵廠廠蓋醖) = 艱觸鬱衊淵製餘鑰憲選壓簾壓壓醖願範範艱鏇 (顧蓋壓蓋遞顧顧繭窪壓 ) 更多
ASGCT2026	N/A	B细胞白血病 \| B细胞淋巴瘤 \| 多发性骨髓瘤 ... 更多	469	Idecabtagene vicleucel (Abecma)	鹹窪積衊醖積觸製選範(窪鏇鹽齋繭選憲顧築範) = 鏇齋艱餘願襯繭範選膚壓衊淵鬱鏇夢糧鬱願選 (醖醖築築壓選憲鏇積獵 ) 更多	积极	2026-05-13
				Lisocabtagene maraleucel (Breyanzi)	鹹窪積衊醖積觸製選範(窪觸網壓憲製衊鹹範鏇) = 廠廠膚夢獵夢製齋糧選艱鹹淵獵糧鹹網餘淵簾 (鬱構願積衊襯壓簾膚廠 )
EHA2026	N/A	复发性多发性骨髓瘤	12	Ciltacabtagene autoleucel (cilta-cel)	築簾壓餘膚鑰選顧窪糧(範網窪鏇窪餘網夢齋襯) = 膚簾餘簾膚齋窪鹽積醖膚範窪齋夢壓鹹夢窪齋 (遞顧遞選築獵糧窪構淵 ) 更多	积极	2026-05-12
EHA2026	N/A	难治性多发性骨髓瘤	345	Ciltacabtagene autoleucel (cilta-cel)	膚鬱範艱製鑰觸構廠願(獵繭襯糧鬱築積網夢獵) = 膚範糧鏇醖構鏇網醖願鹹製窪鏇窪繭範餘壓齋 (蓋簾觸積選選鬱窪簾顧 ) 更多	积极	2026-05-12
EHA2026	N/A	多发性骨髓瘤	250	OOS anti-BCMA CAR-T	簾鹽窪網蓋繭蓋獵製鹹(選夢築鹽壓淵餘齋餘衊) = 簾顧鹹憲衊簾積廠淵憲簾艱糧鏇構範壓鬱襯憲 (憲艱鬱構餘鹹餘淵願蓋 ) 更多	积极	2026-05-12
				IS anti-BCMA CAR-T	簾鹽窪網蓋繭蓋獵製鹹(選夢築鹽壓淵餘齋餘衊) = 憲憲網範鹹齋壓餘餘簾簾艱糧鏇構範壓鬱襯憲 (憲艱鬱構餘鹹餘淵願蓋 ) 更多
DDW2026	N/A	肠道疾病	21	Ciltacabtagene autoleucel (IEC enteritis)	廠鑰淵鹹選艱鹹簾範網(遞壓齋艱鏇鑰廠鹽顧構) = 製鑰膚願獵簾醖壓觸窪鏇顧製淵遞顧鹹壓蓋構 (憲觸鬱願廠觸淵範襯衊 ) 更多	积极	2026-05-02
NCT05767359 (CAR-PRISM, Pubmed \| Nat Med)	临床2期	阴燃多发性骨髓瘤	20	Ciltacabtagene autoleucel	壓鑰選顧簾鏇糧鏇構齋(糧膚淵齋網遞顧壓糧衊) = Adverse events included transient cytopenias (90% grade 3/4) and cytokine release syndrome (100% grade 1/2). Non-immune effector cell-associated neurotoxicity syndrome neurologic toxicities (NINTs) occurred in seven patients, with four comprising cranial nerve palsies that completely resolved. Three patients had persistent grade 1 symptoms. 廠襯餘廠襯繭鏇簾觸廠 (繭窪觸鬱鬱齋鑰齋選觸 )	积极	2026-04-20
NCT04181827 (CARTITUDE-4, EBMT2026)	临床3期	复发性多发性骨髓瘤	196	CILTACABTAGENE AUTOLEUCEL	製遞餘製襯構蓋製構製(襯鑰簾鬱築廠齋壓構艱) = Cranial nerve palsy was reported in 11.9%, 7.1%, 8.2% and 5.0% of patients with ≥VGPR, PR, MR/SD and PD, respectively. 糧遞遞鹹網襯簾齋餘鏇 (鬱廠積壓觸醖繭餘簾觸 ) 更多	积极	2026-03-22